5 reasons to be a Sanofi shareholder



Sanofi: a global healthcare leader

A leading player in Diabetes, Vaccines, Rare Diseases, Multiple Sclerosis, Consumer Healthcare and Emerging Markets.

€35,055m

2017
Company sales

€6,964m

2017
Business net income

€5,54

2017
Business EPS

Every day, more than 100,000 employees in more than 100 countries are committed to preventing diseases with vaccines, to offering innovative treatments and to supporting both those with rare diseases and the millions of people with chronic diseases.

Innovative Research and Development

A robust pipeline meeting unsatisfied medical needs which may support long-term growth.


As of May 2, 2018

Solid financial performance

Value-creating acquisitions while maintaining financial discipline.

« After important changes since 2015, we are on track to return to growth in 2018 »

Olivier Brandicourt, Chief Executive Officer
2017 Annual Results Presentation

Consistent dividend increase for 24 years and high dividend yield

Strong commitment to regular shareholder returns

Dividends

A responsible company

Focused on patients’ needs and committed to improving access to healthcare for all people across the globe.

responsibility

Discover Sanofi

Being a shareholder

Being a shareholder

Shareholder Handbook 2018

Shareholder Handbook 2018

Disclaimer: the information presented in this section is not an offer or a sollicitation of an offer to buy, to sell or to subscribe for any Sanofi securities. This information shall not constitue a sollicitation to invest.